Vantage logo

A new reality for Immunocore

A private raise should crystallise what was already known to have been a valuation comedown for Immunocore and its troubled investor Neil Woodford.

Vantage logo

Six burning Otezla questions

Planned divestment of Celgene’s psoriasis blockbuster means instant cashback for Bristol, a result the markets see as a win-win-win.